Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Sanmartín O, Beato C, Suh-Oh HJ, Aragón I, España A, Majem M, Segura S, Gúrpide A, Botella R, Grávalos C. Sanmartín O, et al. Among authors: aragon i. Actas Dermosifiliogr (Engl Ed). 2019 Jul-Aug;110(6):448-459. doi: 10.1016/j.ad.2019.01.011. Epub 2019 Apr 19. Actas Dermosifiliogr (Engl Ed). 2019. PMID: 31010573 English, Spanish.
Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors.
Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez-Garcia J, Hernando J, Espinosa J, de Castro EM, Ghanem I, Beato C, Blasco A, Garrido M, Mondéjar R, Arcusa MÁ, Aragón I, Manzano A, Sevillano E, Castañón E, Ayala F; Supportive Care Working Group of the Spanish Society of Medical Oncology (SEOM). Carmona-Bayonas A, et al. Among authors: aragon i. Clin Transl Oncol. 2017 Mar;19(3):386-395. doi: 10.1007/s12094-016-1540-y. Epub 2016 Aug 15. Clin Transl Oncol. 2017. PMID: 27525978
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C, Sanmartín O, Gúrpide A, España A, Majem M, Suh Oh HJ, Aragón I, Segura S, Beato C, Botella R. Grávalos C, et al. Among authors: aragon i. Clin Transl Oncol. 2019 May;21(5):556-571. doi: 10.1007/s12094-018-1953-x. Epub 2018 Oct 3. Clin Transl Oncol. 2019. PMID: 30284232 Free article. Review.
Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
Lozano R, Castro E, Lopez-Campos F, Thorne H, Ramirez-Backhaus M, Aragon IM, Cendón-Florez Y, Gutierrez-Pecharroman A, Salles DC, Romero-Laorden N, Lorente D, González-Peramato P, Calatrava A, Alonso C, Anido U, Arévalo-Lobera S, Balmaña J, Chirivella I, Juan-Fita MJ, Llort G, Y Cajal TR, Almagro E, Alameda D, López-Casas PP, Herrera B, Mateo J, Pritchard CC, Antonarakis ES, Lotan TL, Rubio-Briones J, Sandhu S, Olmos D. Lozano R, et al. Among authors: aragon im. Eur J Cancer. 2023 May;185:105-118. doi: 10.1016/j.ejca.2023.02.022. Epub 2023 Mar 5. Eur J Cancer. 2023. PMID: 36972661
PDE5A Polymorphisms Influence on Sildenafil Treatment Success.
Marchal-Escalona C, Herrera-Imbroda B, Clemente-Postigo M, Alcaide-Torres J, Quiñonero A, Marchal M, Queipo-Ortuño MI, Aragón IM, Martín-Morales A, Lara MF, Cardona F. Marchal-Escalona C, et al. J Sex Med. 2016 Jul;13(7):1104-10. doi: 10.1016/j.jsxm.2016.04.075. Epub 2016 May 24. J Sex Med. 2016. PMID: 27235284
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer Patients.
Oliva L, Lozano R, Llácer C, Aragón I, Pajares BI, Sáez MI, Herrera-Imbroda B, Montesa A, Hernández D, Villatoro R, Otero A, Correa R, Grau G, Peinado P, Pacheco MI, García-Galisteo E, Rueda A, Machuca FJ, Alba E, Márquez-Aragonés A, Olmos D, Castro E. Oliva L, et al. Among authors: aragon i. Eur Urol Oncol. 2021 Apr;4(2):315-318. doi: 10.1016/j.euo.2019.06.019. Epub 2019 Jul 13. Eur Urol Oncol. 2021. PMID: 31307957
HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies.
Khalaf DJ, Aragón IM, Annala M, Lozano R, Taavitsainen S, Lorente D, Finch DL, Romero-Laorden N, Vergidis J, Cendón Y, Oja C, Pacheco MI, Zulfiqar M; PROREPAIR-B investigators; Gleave ME, Wyatt AW, Olmos D, Chi KN, Castro E. Khalaf DJ, et al. Among authors: aragon im. Ann Oncol. 2020 Sep;31(9):1186-1197. doi: 10.1016/j.annonc.2020.06.006. Epub 2020 Jun 20. Ann Oncol. 2020. PMID: 32574722 Free article. Clinical Trial.
59 results